Thank you very much to the honourable member. That is an excellent question.
Right off the top, one of the initiatives that we've been doing throughout the course of all this has been a highly integrated approach across various ministries to deal with this, specifically in working very closely with ISED as well as NRC in the area of vaccine development. Canada has world-leading expertise within the National Research Council on the development of vaccines and scaling up, so much of the $275 million in funding that you saw released by the government was really toward developing the industrial response so that Canada would have the capacity to provide therapeutics when and if they are available, specifically in the area of vaccines. I'll come back to that in just a second.
With respect to the funding that went out into the rapid response program, it was across a broad range of research approaches that were informed by our international colleagues. We continue to be aware and interlinked on the international front with initiatives being brought forward. For instance, to return to the core of your question on the vaccines, there are a number of different vaccines and different approaches that are available worldwide and are being looked at, at this moment. As we begin to look at scaling up for the ones that are the most promising in trials, we will be part of international consortia on those, with the ability to actually produce them in Canada.